伏诺拉生在治疗幽门螺杆菌感染中的研究进展  

Advances in the Study of Vonoprazan in the Treatment of Helicobacter pylori Infection

作　　者：孙梓铭 刘希双[2] 

机构地区：[1]青岛大学医学部,山东 青岛 [2]青岛大学附属医院消化内科,山东 青岛

出　　处：《临床医学进展》2024年第3期1145-1153,共9页Advances in Clinical Medicine

摘　　要：幽门螺杆菌(Hp)是一种定植于胃内的致病菌,其感染被证实与胃腺癌、慢性胃炎、消化性溃疡、黏膜相关淋巴组织淋巴瘤等多种胃肠疾病密切相关。近年来,随着耐药性的增加,Hp的根除率在不断下降,临床也在不断探索新的治疗药物。伏诺拉生(VPZ)是一种新型钾离子竞争性酸阻滞剂,表现出了比质子泵抑制剂(PPI)更显著、快速且持久的抑酸作用。因此,本文通过对VPZ的药理学机制、与PPI的比较、VPZ根除Hp方案的临床研究及安全性等方面作一综述。Helicobacter pylori (Hp) is a pathogenic bacterium that colonizes the stomach, and its infection is closely associated with a variety of gastrointestinal diseases, including gastric adenocarci-noma, chronic gastritis, peptic ulcers, and mucosa-associated lymphoid tissue lymphoma. In recent years, the eradication rate of Hp has decreased with the increase of drug resistance, and new therapeutic agents are being explored clinically. Vonoprazan (VPZ) is a novel potassi-um-competitive acid blocker that exhibits a more significant, rapid, and long-lasting acid inhib-itory effect than PPIs. Therefore, this article reviews the pharmacological mechanism of VPZ, its comparison with PPIs, and the clinical studies and safety of the VPZ Hp eradication regimen.

关 键 词：幽门螺杆菌 伏诺拉生 质子泵抑制剂 

分 类 号：R73[医药卫生—肿瘤]